Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 12, 2023

Endocrine Therapy With or Without Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+/HER2− Metastatic Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial
J. Clin. Oncol 2023 May 19;[EPub Ahead of Print], K Kalinsky, MK Accordino, C Chiuzan, PS Mundi, E Sakach, C Sathe, H Ahn, MS Trivedi, Y Novik, A Tiersten, G Raptis, LN Baer, SY Oh, AB Zelnak, KB Wisinski, E Andreopoulou, WJ Gradishar, E Stringer-Reasor, SA Reid, A O'Dea, R O'Regan, KD Crew, DL Hershman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading